Building a Biopharmaceutical Company
Programs in three large and growing markets
- Diabetes
- Obesity
- Cardiovascular Disease
Two late-stage, first-in-class, development programs
- SYMLIN® (pramlintide acetate)
- Type 1 and insulin-using type 2 diabetes
- Exenatide (exendin-4)
Building an organization for the future